Noun
nivolumab (uncountable)
(pharmacology) a human IgG4 anti-PD-1 monoclonal antibody, acting as a checkpoint inhibitor, thus allowing activated T cells to attack cancer cells
In patients with less than 1% PD-L1 expression, the progression-free survival (PFS) benefit of nivolumab plus chemotherapy versus chemotherapy was enhanced with high TMB (10 or more mutations/Mb). Source: Internet
Tumors shrank in 17% of patients treated with nivolumab and 26% of those treated with nivolumab and ipilimumab. Source: Internet